| Organ System | Specific Manifestation | Age of Onset | Frequency in PXE Patients | Severity | Progression Pattern | HPO Terms (suggested) | Quality of Life Impact |
|---|---|---|---|---|---|---|---|
| Integumentary / Skin | Small yellow papules on neck and flexural areas | Typically childhood to adolescence; often first clinical sign (pqac-00000003, pqac-00000006) | Common / usually initial presenting sign; “almost always” first clinical sign in review literature (pqac-00000003) | Usually mild medically, cosmetically significant | Progressive: isolated papules coalesce into plaques over time (pqac-00000003, pqac-00000004, pqac-00000006) | HP:0000987 Skin papule; HP:0010783 Abnormality of the skin of the neck; HP:0000978 Bruising susceptibility not applicable; HP:0001065 Generalized lax skin not initial | Cosmetic burden; may cause distress and social/self-image impact, but usually less disabling than ocular/vascular disease (pqac-00000004, pqac-00000009) |
| Integumentary / Skin | Lax, wrinkled, redundant skin in flexural areas | Usually follows papules, often from adolescence/early adulthood onward (pqac-00000003, pqac-00000006) | Common in established disease; qualitative frequency high in clinical descriptions (pqac-00000003, pqac-00000004) | Mild to moderate | Progressive chronic change with loss of recoil and leathery/sagging skin (pqac-00000004, pqac-00000006) | HP:0000973 Wrinkled skin; HP:0001007 Redundant skin; HP:0001513 Cutis laxa-like skin changes | Mainly cosmetic and psychosocial impact; may affect body image and clothing comfort (pqac-00000004, pqac-00000009) |
| Ophthalmologic | Peau d’orange / early Bruch’s membrane change | Often precedes angioid streaks; can occur in young patients | Observed in 96% of patients with skin signs in one study cited by review (pqac-00000006) | Usually mild initially | Early marker that may precede more vision-threatening retinal disease (pqac-00000006, pqac-00000012) | HP:0030937 Abnormality of Bruch membrane; HP:0100012 Retinal abnormality | Usually limited direct impact initially, but clinically important as precursor of later visual morbidity (pqac-00000006, pqac-00000012) |
| Ophthalmologic | Angioid streaks | Usually years after skin changes; often early adult life (pqac-00000006) | Characteristic ocular feature; common in affected adults (pqac-00000003, pqac-00000006) | Moderate to severe because of risk of CNV and vision loss | Progressive; may become symptomatic when approaching fovea (pqac-00000006) | HP:0007932 Angioid streaks of the fundus | Major threat to vision; central visual tasks and reading/driving may become impaired (pqac-00000006) |
| Ophthalmologic | Choroidal neovascularization (CNV) | Usually after angioid streaks, often adulthood | Common complication of calcified Bruch’s membrane in progressing disease; exact percentage not given in retrieved sources (pqac-00000003, pqac-00000004) | Severe | Progressive/episodic with hemorrhage and scarring if untreated (pqac-00000004, pqac-00000006) | HP:0007754 Choroidal neovascularization | High impact; anti-VEGF treatment burden and risk of central vision loss reduce daily functioning (pqac-00000003, pqac-00000004) |
| Ophthalmologic | Progressive loss of visual acuity / central vision loss / blindness in late-stage disease | Often adulthood, with severe impairment potentially by 40s if untreated (pqac-00000004) | Important late complication; exact prevalence not provided in retrieved contexts (pqac-00000003, pqac-00000004) | Severe | Progressive due to hemorrhage, scarring, and macular atrophy (pqac-00000004, pqac-00000012) | HP:0000505 Visual impairment; HP:0000529 Progressive visual loss; HP:0000618 Blindness | Very high impact; vision-related quality of life is markedly reduced, and visual impairment was associated with major degradation in vision-related QoL (pqac-00000006) |
| Cardiovascular / Vascular | Arterial calcification (including lower-limb and coronary calcification) | Usually becomes apparent years after skin/ocular changes; increases with age (pqac-00000005, pqac-00000006) | Common hallmark in adult PXE; severity strongly age-dependent (pqac-00000005, pqac-00000014) | Moderate to severe | Progressive, chronic, age-related accumulation; major determinant appears to be time/age (pqac-00000005) | HP:0004958 Arterial calcification; HP:0005117 Vascular calcification | Contributes to vascular morbidity, reduced exercise capacity, and anxiety about cardiovascular events (pqac-00000000, pqac-00000005) |
| Cardiovascular / Vascular | Peripheral artery disease (PAD) | Typically adulthood after earlier skin/eye findings (pqac-00000003, pqac-00000006) | Major cause of morbidity; common qualitative feature (pqac-00000005, pqac-00000006) | Moderate to severe | Progressive chronic vascular disease; may require intervention in advanced stages (pqac-00000013) | HP:0004939 Peripheral arterial insufficiency | Limits walking and physical activity; contributes to reduced participation in social/occupational activities (pqac-00000000, pqac-00000006) |
| Cardiovascular / Vascular | Intermittent claudication | Usually adulthood | Cardinal symptom of lower-extremity arterial disease; common qualitative feature (pqac-00000004, pqac-00000006) | Moderate | Progressive with worsening PAD; exertional symptom burden (pqac-00000004, pqac-00000006) | HP:0002579 Intermittent claudication | Substantial mobility limitation and exercise intolerance; important contributor to reduced QoL (pqac-00000000, pqac-00000006) |
| Cardiovascular / Vascular | Hypertension | Usually adulthood | Reported but less consistently emphasized than calcification/PAD; exact percentage not provided (pqac-00000004, pqac-00000017) | Mild to moderate, can contribute to vascular risk | Chronic; may coexist with arterial disease (pqac-00000017) | HP:0000822 Hypertension | Adds long-term cardiovascular risk and treatment burden (pqac-00000004, pqac-00000017) |
| Neurologic / Cerebrovascular | Ischemic stroke risk / cerebrovascular disease | Usually older adults; risk appears elevated relative to general population (pqac-00000006, pqac-00000008) | 15% in one cohort of 38 PXE patients; 7% in another cohort of 100, relative risk 3.6 vs general population (pqac-00000006) | Severe | Episodic vascular complication on background of progressive vasculopathy (pqac-00000006, pqac-00000008) | HP:0002140 Ischemic stroke; HP:0001297 Cerebrovascular accident | Potentially devastating disability; major anxiety source and contributor to long-term morbidity (pqac-00000006, pqac-00000008) |
| Gastrointestinal | Gastrointestinal bleeding (especially stomach) | Usually adulthood | Around 15% of PXE patients vs ~0.1% in general population, according to review summary (pqac-00000006) | Moderate to severe; potentially acute | Episodic complication | HP:0002239 Gastrointestinal hemorrhage; HP:0002573 Hematemesis if present | Acute morbidity, hospitalization risk, and anxiety regarding bleeding events (pqac-00000006) |


*Table: This table summarizes the major clinical manifestations of pseudoxanthoma elasticum across skin, ocular, vascular, neurologic, and gastrointestinal systems. It highlights onset, frequency, progression, suggested HPO annotations, and likely quality-of-life effects for knowledge base curation.*